GMAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the investor's long-term strategy and beginner level, Genmab A/S (GMAB) is not a strong buy at this moment. The stock has faced recent price declines, lacks immediate trading signals, and has mixed financial performance. While analysts are optimistic about its long-term prospects, the near-term catalysts are limited, and the technical indicators suggest a neutral trend. A 'hold' recommendation is appropriate for now.
The MACD is positive at 0.321 but contracting, indicating weakening momentum. RSI is neutral at 53.82, and moving averages are converging, showing no strong directional trend. Support is at 26.983, and resistance is at 29.183. The stock is trading near its pivot point of 28.083, suggesting limited immediate upside.
Analysts see 2026 as a 'catalyst-rich' year with multiple clinical readouts and potential sales growth.
DARZALEX therapy achieved strong Q1 sales of $3.96 billion, contributing significant royalties.
Wolfe Research and Wells Fargo view the current dip as a buying opportunity.
Recent price drop of -3.41% in regular trading and -0.78% in pre-market.
Financial performance in Q4 2025 showed a significant drop in net income (-94.38% YoY) and EPS (-94.26% YoY).
Stock trend analysis indicates a likelihood of further short-term declines (-2.46% in the next month).
In Q4 2025, revenue increased by 14.63% YoY to $1.058 billion, but net income dropped sharply by -94.38% YoY to $31 million. EPS also fell by -94.26% YoY to 0.49, and gross margin declined slightly to 92.34%.
Analysts are generally bullish with multiple Buy ratings and price targets ranging from $32 to $41.50. However, there are concerns about near-term challenges, including the loss of exclusivity in 2029 and lower Epkinly estimates. Analysts emphasize 2026 as a critical year for the company with key catalysts.
